David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.
Upon completion of this activity, participants should be able to:
Intermediate Atypical Carcinoma: Novel Histological Subtype of mCRPC in Patients Resistant to Androgen Receptor Agonists
KEYNOTE-012: Pembrolizumab Shows Promising Antitumor Activity and Safety in Advanced Urothelial Cancer
SYNERGY: Custirsen in Poor-Prognosis mCRPC
Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.